Table 3 |
||||||
|
Distribution of tumor characteristics, and recent mammography among current users of menopausal hormone therapy by type and duration |
||||||
| Therapy |
Duration |
|||||
|
|
|
|||||
| Estrogen–progestin |
Estrogen alone |
P valuea |
<5 years |
≥ 5 years |
P valuea |
|
|
|
||||||
| Total |
422 |
92 |
238 |
284 |
||
| Recent mammography |
||||||
| Yes |
301 (75) |
55 (66) |
0.11 |
171 (76) |
189 (70) |
0.13 |
| No |
102 (25) |
28 (34) |
53 (24) |
80 (30) |
||
| Tumor size |
||||||
| ≤ 10 mm |
125 (30) |
23 (25) |
61 (26) |
90 (32) |
||
| 11 to 20 mm |
186 (44) |
51 (56) |
0.19 |
101 (43) |
139 (49) |
0.010 |
| 21 to 50 mm |
102 (24) |
15 (16) |
70 (30) |
49 (17) |
||
| >50 mm |
8 (2) |
2 (2) |
5 (2) |
5 (2) |
||
| Lymph node involvement |
||||||
| 0 lymph nodes |
289 (70) |
60 (67) |
162 (69) |
191 (69) |
||
| 1 to 3 lymph nodes |
86 (21) |
24 (27) |
0.38 |
47 (20) |
65 (23) |
0.36 |
| >3 lymph nodes |
39 (9) |
6 (7) |
25 (11) |
21 (8) |
||
| Grade |
||||||
| 1 |
69 (25) |
10 (15) |
21 (13) |
57 (31) |
||
| 2 |
99 (37) |
32 (48) |
0.11 |
57 (36) |
76 (42) |
<0.0001 |
| 3 |
103(38) |
24 (36) |
80 (51) |
50 (27) |
||
| Histology |
||||||
| Ductal |
272 (66) |
61 (68) |
17 (74) |
166 (60) |
||
| Lobular |
69 (17) |
10 (11) |
0.37 |
34 (15) |
46 (17) |
0.0007 |
| Other |
73 (18) |
19 (21) |
27 (12) |
66 (24) |
||
| Estrogen receptor (ER), progesterone receptor (PR) status |
||||||
| ER-PR- |
45 (15) |
9 (16) |
34 (20) |
21 (11) |
||
| ER+PR- |
35 (12) |
5 (9) |
0.93 |
25 (15) |
15 (8) |
0.0062 |
| ER-PR+ |
19 (6) |
4 (7) |
13 (8) |
10 (5) |
||
| ER+PR+ |
196 (66) |
39 (68) |
99 (58) |
140 (75) |
||
|
|
||||||
|
Data presented as n (%). aGlobal chi-squared P value for type and duration, respectively. |
||||||
|
Rosenberg et al. Breast Cancer Research 2008 10:R78 doi:10.1186/bcr2145 |
||||||
